Compare Global X FTSE Southeast Asia ETF (ASEA) vs Canopy Growth Corp (CGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Canopy Growth Corp — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.75, while Canopy Growth Corp trades at $0.97 (market cap $407.38M). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| ASEA | CGC | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $20.65 | $1.92 |
52-Week Low | $16.31 | $0.86 |
Market Cap | — | $407.38M |
Enterprise Value | — | $346.82M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
Canopy Growth (CGC) trades at $0.97, down 0.28% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses. Cash flow remains negative, but the balance sheet improved with a debt-to-asset ratio of 33.13% in 2025. Analyst sentiment is divided, with 33% buy ratings amid ongoing profitability challenges and potential reverse stock split discussions.
The outlook for CGC hinges on achieving profitability and navigating regulatory hurdles, with projected revenue growth to $285 million in 2026 offering a potential catalyst. Key risks include persistent losses, high debt, and Nasdaq compliance concerns, while institutional interest remains cautious. Investors should weigh the speculative turnaround potential against significant financial and operational headwinds in the volatile cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
